Navigation Links
Biozoom Enters Into Commercial Phase of Scanner Production

AGOURA HILLS, Calif., June 24, 2013 /PRNewswire/ -- Biozoom (OTC QB: BIZM) creator of the world's first of its kind portable, handheld device for real-time biofeedback, announced today that the device has entered commercial production. "The Biozoom scanner has captured the attention of so many organizations that production has moved from prototype to commercial scale," said Biozoom CTO, Dr. Wolfgang Kocher. The first shipment of scanners is expected to arrive in September. "They will be used to extend our test marketing with key commercial, healthcare and governmental entities."

The Biozoom scanner non-invasively measures and analyzes the biomarkers critical to understanding, managing and improving a user's health and wellness. The prototype units have been validated in clinical trials and used at respected European institutions. The first commercially produced scanners are expected to be used for large-scale studies by major multinational cosmetics and consumer goods producers, as well as large employers.

A portion of the first shipment will be dedicated to market testing in the United States, where health and wellness represent a $150 billion opportunity. "People everywhere want to live longer and healthier lives. A recent study by the Consumer Electronics Association indicated that 55% of online consumers in the US used some form of fitness electronics last year, and 37% anticipate buying a wellness related device this year," said Dr. Kocher.

Biozoom's innovation has been the successful miniaturization of reflection spectroscopy. The development of the biofeedback scanner has its roots in patented optics produced by Carl Zeiss, which overcome the challenges of portable, handheld spectroscopy. At the press of a button, the transdermal scanner collects and sends spectroscopic data to Biozoom's servers, which instantly return both results and wellness support coaching to the user.

"We have reached an exciting milestone," said CEO Hardy Hoheisel. "The first commercially produced units will include all of the patented components and will prove the feasibility of low-cost mass production."

Because the Biozoom scanner measures anti-aging factors including skin moisture and nutritional absorption, "it is of great interest to the cosmetics industry," said Dr. Kocher. "At the same time, the scanner gives new insight into the overall health and wellbeing of users by measuring antioxidant levels, stress responses and much more. Several large organizations have expressed interest in using the scanner to understand and support the health of their employees.  By focusing on wellness and disease prevention, they can use Biozoom to help drive down healthcare costs and absenteeism due to preventable illness."   

About Biozoom
Biozoom is an innovative technology development company, specializing in the commercialization of our advances in mobile spectroscopy. Our intellectual property portfolio and ongoing research are positioned to apply Biozoom's technology breakthroughs to a wide range of markets. Our first consumer product, the Biozoom scanner, gives people the feedback they need to manage their health, wellness and fitness on demand. Tested in leading health institutions, our scanner is the first of its kind—a handheld, transdermal device for measuring biomarkers, including antioxidant levels, at the click of a button. Scan results—and customized wellness coaching based on those biomarkers—are sent instantly to a smartphone or online account. The scanner will enable leaders in the health and wellness industry to create new levels of customer loyalty and revenues as a result. For more information, visit

This press release contains "forward-looking statements". Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future, and specifically references to future potential purchase orders and re-orders from consumers and distributors. The reader can identify these forward-looking statements by forward-looking words such as "may," "will," "expect," "potential," "anticipate," "forecast," "believe," "estimate," "project," "plan," "continue" or similar words. The reader should read statements that contain these words carefully because they discuss future expectations, contain projections of future results of operations or of financial condition, or state other forward-looking information. Forward-looking statements include, but are not limited to, statements regarding potential products, customers, revenues, expansion efforts, and future plans and objectives of Biozoom, Inc. ("Biozoom"). The risk factors listed in our disclosure documents and the cautionary language therein provide examples of risks, uncertainties and events that may cause actual results to differ materially from the expectations and projections described by Biozoom in its forward-looking statements. Actual results relating to, among other things, product launch, sales, customer acceptance and market share could differ materially from those currently anticipated in such statements. Factors affecting forward-looking statements include: consumer preferences, competition from more established brands, ability to develop market share; changes in the operating costs; changes in economic conditions, foreign exchange and other financial markets; changes of the interest rates on borrowings; changes in the investments levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Biozoom operates; technological, mechanical and operational difficulties encountered in connection with Biozoom's development activities; and labor relation matters and costs. The reader should refer to the risk disclosures set out in the periodic reports and other disclosure documents filed by Biozoom from time to time with the Securities and Exchange Commission and other regulatory authorities.

SOURCE Biozoom, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Monoclonal Antibody with Xencors High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia
2. Energy Department announces 5-year renewal of funding for Bioenergy Research Centers
3. New Research Conducted by University Cancer Centers Links BP Refinery Incident to Increase Occurrence of Cancer in Texas City
4. Astrochemistry enters a bold new era with ALMA
5. Engineering research centers awarded $55.5 million to innovate in nanoscale science and engineering
6. 2 UNC faculty receive Autism Centers of Excellence grants for new research
7. University of Minnesota receives $13.1 million in DOE funding for 2 new nationwide centers
8. As TB grows more difficult to control, vaccine candidate to prevent disease enters clinical testing
9. Saladax Biomedical Enters into Master Collaboration Agreement with Bristol-Myers Squibb
10. BioNano Genomics Appoints Dr. Fahim Amini As Vice President Commercial Operations EMEA
11. Molecular Imaging Agents: Targets, Technology, Markets, and Commercial Opportunities
Post Your Comments:
(Date:11/12/2015)...  Arxspan has entered into an agreement with ... use of its ArxLab cloud-based suite of biological ... will support the institute,s efforts to electronically manage ... internally and with external collaborators. The ArxLab suite ... Institute,s electronic laboratory notebook, compound and assay registration, ...
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
(Date:11/9/2015)...  Synaptics Inc. (NASDAQ: SYNA ), the leading ... into the automotive market with a comprehensive and dedicated ... consumer electronics human interface innovation. Synaptics, industry-leading touch controllers, ... automotive industry and will be implemented in numerous locations ... , Japan , and ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced  today ... rights plan (Rights Plan) in an effort to preserve ... under Section 382 of the Internal Revenue Code (Code). ... use of its NOLs could be substantially limited if ... Section 382 of the Code. In general, an ownership ...
(Date:11/25/2015)... 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... CEO of Neurocrine Biosciences, will be presenting at the ... New York . .   ... 5 minutes prior to the presentation to download or ... will be available on the website approximately one hour ...
(Date:11/25/2015)... 2015 The Global Genomics ... professional and in-depth study on the current state ... ) , The report ... definitions, classifications, applications and industry chain structure. The ... markets including development trends, competitive landscape analysis, and ...
(Date:11/24/2015)... Calif. , Nov. 24, 2015 Cepheid ... will be speaking at the following conference, and invited ... New York, NY      Tuesday, December 1, 2015 ... New York, NY      Tuesday, December 1, 2015 ... Jaffray Healthcare Conference, New York, NY ...
Breaking Biology Technology: